Difference between revisions of "Part:BBa K3733007"
Yuanhui Sun (Talk | contribs) |
Yuanhui Sun (Talk | contribs) (→Materials and Method) |
||
| Line 11: | Line 11: | ||
===Materials and Method=== | ===Materials and Method=== | ||
<p>1.Plasmids Construction</p> | <p>1.Plasmids Construction</p> | ||
| − | <p>< | + | <p><br></p> |
<p>LTA-coding sequence is constructed using primers by overlap extension PCR. The constructed fragment is ligated to the target site in pET28 by PCR and homologous recombination. The correct construction is confirmed by sequencing.</p> | <p>LTA-coding sequence is constructed using primers by overlap extension PCR. The constructed fragment is ligated to the target site in pET28 by PCR and homologous recombination. The correct construction is confirmed by sequencing.</p> | ||
Revision as of 13:46, 20 October 2021
LTA: A novel antimicrobial peptide
LTA is a novel antimicrobial peptide (AMP), whose design was based on combing the active centers of a ride range of AMPs, including LL-37, YW12D, innate defense regulator 1, and cathelicidin 2 with thymopentin or the active center of thymosin alpha 1 (Tα1). It could neutralize Lipopolysaccharides (LPS), thus effectively blocking the downstream inflammation pathway.
Design
This part has undergone codon optimization based on the bias of Escherichia coli. As the original coding sequence of LTA doesn’t contain the start codon and termination codon, they are then added to guarantee the expression of the protein.
Materials and Method
1.Plasmids Construction
LTA-coding sequence is constructed using primers by overlap extension PCR. The constructed fragment is ligated to the target site in pET28 by PCR and homologous recombination. The correct construction is confirmed by sequencing.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]